Improving tumour targeting and decreasing normal tissue uptake by optimizing the stoichiometry of a two-step biotinylated-antibody/streptavidin-based targeting strategy: Studies in a nude mouse xenograft model

作者
Anthony Maraveyas,Gail Rowlinson‐Busza,Samuel J. Murray,Agamemnon A. Epenetos
出处
期刊:International Journal of Cancer [Wiley]
卷期号:78 (5): 610-617 被引量:8
标识
DOI:10.1002/(sici)1097-0215(19981123)78:5<610::aid-ijc14>3.0.co;2-t
摘要

We aimed to study in detail the in vivo stoichiometry of the individual elements of the 2-step streptavidin based approach to tumour targeting, in a nude mouse xenograft model, by the administration of a first step consisting of biotinylated anti-tumour specific antibody and a second step consisting of streptavidin. This process was undertaken to identify the optimum conditions for radiotherapeutic tumour targeting using this approach. Antibody was biotinylated to various degrees (1-25 biotins per antibody). Protein stoichiometry of the 2 steps was studied over a range of 2 logs. Both steps, i.e., the biotinylated-antibody (1st step) and streptavidin (2nd step) were radiolabelled (125I and 131I, respectively). A 24-hr interval between 1st and 2nd step was studied, animals being killed 24 hr after the 2nd step. Streptavidin excess led to a decrease in levels of monobiotinylated-antibody in the circulation and in the tumour. Biotinylated-antibody excess led to an increase in circulating levels of streptavidin, a decrease in renal uptake of streptavidin and increased targeting of streptavidin to tumour. At a constant protein molar ratio of biotinylated antibody to streptavidin of 10:1, increasing biotinylation density resulted in an increase in circulating levels, increase in tumour uptake, decrease in renal uptake and increase in liver uptake of streptavidin. As early as 24 hr, the tumour-to-blood ratios of streptavidin already exceeded 1 (max 1.27). Compared with antibody tumour-to-blood ratios, they were better by a factor of between 2 and 3. Tumour-to-normal tissue ratios of radiolabelled streptavidin (with the exception of liver) were also significantly improved when polybiotinylated-antibody was administered first. We have thus shown that the 2-step biotinylated antibody/streptavidin approach can lead to a significant increase in absolute amounts of activity in the tumour under appropriate stoichiometric conditions. This was accompanied by high levels of circulating streptavidin and relatively favourable tumour-to-blood and normal tissue ratios of streptavidin.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wyb发布了新的文献求助10
刚刚
熊清怡完成签到,获得积分10
刚刚
努力向上的曼完成签到,获得积分10
刚刚
我是老大的应助被知性的采珊采纳,获得10
1秒前
天天快乐的应助被科研小郭采纳,获得40
1秒前
T1aNer299完成签到,获得积分10
2秒前
快乐小夏发布了新的文献求助10
2秒前
40780发布了新的文献求助10
2秒前
闫晓涵完成签到 ,获得积分10
2秒前
魏芷容完成签到,获得积分10
3秒前
molihuakai的应助被HS采纳,获得30
4秒前
04d发布了新的文献求助10
4秒前
SciGPT的应助被hehe采纳,获得10
4秒前
22336的应助被云舒采纳,获得20
5秒前
5秒前
5秒前
wizard完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
6秒前
ROC完成签到,获得积分10
6秒前
绒绒完成签到,获得积分20
7秒前
科研通AI6.4的应助被coast采纳,获得10
7秒前
一只耳完成签到,获得积分10
8秒前
amy完成签到,获得积分10
8秒前
8秒前
重要的尔安完成签到 ,获得积分10
8秒前
bkagyin的应助被贪玩诗云采纳,获得10
9秒前
9秒前
贪玩的秋柔的应助被daomaihu采纳,获得100
9秒前
Akim的应助被背包小熊采纳,获得10
9秒前
可爱的不斜的应助被daomaihu采纳,获得100
9秒前
曹操发布了新的文献求助10
9秒前
大个的应助被V-Chase采纳,获得10
9秒前
9秒前
10秒前
zhuyili发布了新的文献求助10
10秒前
丘比特的应助被科研通管家采纳,获得10
10秒前
英俊的铭的应助被沐0626采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Aspects of Post-SPE Phonology 2000
Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals 888
Rosenblum, Global Change Biology 800
Holistic Discourse Analysis, Second Edition by Robert E. Longacre (2012-09-10) 666
Berberine regulates the TLR4 signaling pathway to suppress hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells 530
Organizational Behavior 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 物理 有机化学 化学工程 内科学 生物化学 复合材料 催化作用 心理学 细胞生物学 无机化学 电极 光电子学 人工智能
热门帖子
关注 科研通微信公众号,转发送积分 7860745
求助须知:如何正确求助?哪些是违规求助? 9378784
关于积分的说明 20718846
捐赠科研通 7460218
什么是DOI,文献DOI怎么找? 3347303
关于科研通互助平台的介绍 2489208
邀请新用户注册赠送积分活动 2372002